Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

ANI Pharmaceuticals, Inc. ANIP

Healthcare — Drug Manufacturers Specialty & Generic

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
14.84
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 1 3 2 1 4 9 1 5 4 3 4 3
Insider Ownership
4.67%

Capital & Financial Ratios

Market Cap
1,750.00
Revenue
978.38
Net Income
108.31
Free Cash Flow
167.52
Net Debt
234.62
Current Ratio
2.91
Debt/Equity
1.02
P/E ratio
15.76
P/S ratio
1.65
P/B ratio
2.70
Past 5Y EPS Growth
(6.27%)
This Y EPS Growth
17.71%
Next Y EPS Growth
12.89%
Next 5Y EPS Growth
14.91%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 221.12 151.20 294.75 375.87
Receivables 162.08 221.73 281.08 274.47
Inventory 111.20 136.78 143.07 143.15
Other 8.02 — — —
519.82 528.46 753.12 825.43
2023 2024 2025 Q'26
Payables 36.68 45.66 62.58 73.83
ST’ Debt 0.85 9.17 17.27 21.33
Other 12.27 0.03 0.17 —
145.48 194.45 278.11 283.66
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 237.46 266.04 — —
—
’25 197.12 211.37 227.81 247.06
883.37
’24 137.43 138.04 148.33 190.57
614.38
’23 106.79 116.55 131.83 131.65
486.82
’22 64.48 73.86 83.82 94.23
316.39
’21 54.52 48.63 52.06 60.93
216.14
’20 49.77 48.47 52.98 57.25
208.48
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 58.38 56.67 — —
—
’25 34.99 75.81 44.06 30.37
185.23
’24 18.27 17.41 12.47 15.86
64.02
’23 21.42 20.63 32.17 44.74
118.96
’22 (18.94) (11.48) 3.62 (4.40)
(31.20)
’21 20.67 0.24 (5.40) (12.18)
3.32
’20 1.71 20.88 (1.61) (5.71)
15.27
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 47.05 53.62 — —
—
’25 15.15 68.90 37.89 28.96
150.90
’24 27.20 12.97 7.03 13.38
60.58
’23 19.07 13.80 27.62 39.96
100.45
’22 (21.12) (12.05) (6.19) (7.54)
(46.91)
’21 19.93 (21.71) (5.98) (9.90)
(17.67)
’20 (55.84) 18.03 (7.42) (7.83)
(53.05)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.28 1.05 — —
—
’25 0.69 0.36 1.13 1.18
3.32
’24 0.82 (0.14) (1.27) (0.55)
(1.04)
’23 0.06 0.29 0.45 0.04
0.85
’22 (1.27) (0.94) (0.55) (0.28)
(3.05)
’21 0.01 (1.17) (0.37) (1.72)
(3.40)
’20 (0.59) (1.03) 0.04 (0.30)
(1.88)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.4
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 22.31 36.54 52.50 52.74 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 48.26 65.89 70.81 99.50 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 600 642 897 970 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.53 0.76 0.68 0.91 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 316.39 486.82 614.38 883.37 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.13% 62.71% 59.27% 61.36% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (62.66) 19.87 (22.21) 95.79 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.81%) 4.08% (3.62%) 10.84% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.90) 18.78 (18.52) 78.34 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 59.65 59.79 81.33 91.42 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.46 27.04 31.80 44.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (3.05) 0.86 (1.04) 3.50 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.92) 6.61 3.31 9.24 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.97) (1.03) (0.18) (1.71) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.88) 5.58 3.14 7.53 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.82 25.42 22.18 26.96 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.26 18.00 19.32 20.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 66.50 0.00 22.55 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.06 2.11 1.74 1.79 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.08 2.38 2.65 2.93 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.80 2.25 2.51 2.16 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.85) 10.89 26.53 12.63 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (31.20) 118.96 64.02 185.23 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.70) (18.51) (3.44) (34.32) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (46.91) 100.45 60.58 150.90 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 244.82 374.34 334.00 475.01 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 286.52 285.67 624.09 617.04 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 233.29 64.55 472.89 322.28 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 338.54 457.60 428.53 540.72 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.47%) 2.06% (1.84%) 5.66% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.86%) 5.62% 0.04% 8.05% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.29%) 4.60% (4.82%) 16.34% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

ANI Pharmaceuticals (ANIP) exemplifies a classic specialty pharma underdog tale, transforming from niche generics to a diversified powerhouse through aggressive acquisitions like the $176 million Novitium Pharma deal in 2023. This strategy ignited revenue from $316 million in 2022 to $487 million in 2023 (54% surge) and $614 million in 2024 (26% more), with per-share revenue more than doubling since 2016 at a 20%+ CAGR. Despite stabilizing gross margins around 59% and productivity gains, the ride has been volatile, marked by pandemic disruptions, integration costs, and inconsistent profitability—net losses exceeding $100 million cumulatively in 2020-2022, a brief 2023 rebound, and another dip in 2024.

Balance sheet pressures loom large, with debt ballooning to $624 million to fund growth, elevating leverage risks amid high interest rates and near-zero ROIC. Insider selling—over $40 million in shares with no buys—adds caution post-revenue beats, contrasting bullish analyst forecasts of $867 million revenue in 2025 (41% growth), profitability turnaround to $65 million net income, and EPS climbing to $3.14, implying 45% average upside from current levels.

Yet, leadership’s M&A track record, rare disease bets like Cortrophin Gel, and projected FCF surges to $102-121 million offer multi-bagger potential if debt is tamed and margins expand. Investors face a high-stakes thriller: rewarding revenue rockets but punishing any acquisition hangover—full analysis unpacks the path forward.

Read full commentary →

ANI Pharmaceuticals, Inc. (ANIP) Latest News

News by impact score

Fine-tune

27 Aug

3 , 7:45 PM
ANI Pharmaceuticals has two positive factors supporting its position but one negative element that could limit growth prospects. Mixed positive and negative factors point to moderate effects on ANIP operations and market standing.

16 Aug

3 , 5:09 AM
ANI Pharmaceuticals addressed the top five analyst questions from its Q2 earnings call. Q2 earnings call questions may influence investor views on ANI's operational and financial outlook.

14 Aug

3 , 1:15 PM
ANI Pharmaceuticals valuation appears low yet Cortrophin launch carries execution risks that could affect ANIP stock purchase decision and future performance. Cortrophin execution risks combined with valuation metrics may moderately influence ANIP financial outlook and investor positioning.

3 , 1:12 PM
ANI Pharmaceuticals cut Cortrophin guidance, raising requirements for stronger second-half growth. Guidance cut on key product creates moderate pressure on near-term financial results and investor views.

3 transcript www.fool.com, 9:14 AM
ANI Pharmaceuticals held its Q2 2026 earnings call to review financial results, operational updates, and outlook. Quarterly earnings calls typically provide financial metrics and guidance that moderately influence short-term stock movement and sentiment.

11 Aug

3 , 9:33 AM
ANI Pharmaceuticals expands rare disease portfolio driving Q2 growth while recalibrating full-year guidance. Rare disease expansion supports revenue growth but guidance recalibration signals tempered outlook for ANI Pharmaceuticals trajectory.

10 Aug

3 , 1:05 PM
ANI Pharmaceuticals beat Q2 earnings estimates but cut its Cortrophin sales outlook, triggering a stock decline. Earnings beat offset by Cortrophin guidance cut creates balanced short-term pressure on stock without altering core trajectory.

8 Aug

4 , 3:09 PM
ANI Pharmaceuticals reported strong Q2 results with a guidance reset, indicating the stock may be 31% undervalued. Strong Q2 results and guidance reset signal major positive shifts in financial trajectory and investor sentiment for ANIP.

7 Aug

4 , 3:01 PM
ANI Pharmaceuticals reported record Q2 2026 revenue during its earnings call, driven by strategic growth initiatives. Record revenue combined with strategic moves signals major positive shifts in ANI's financial trajectory and investor outlook.

4 investorshub.advfn.com, 9:59 AM
ANI Pharmaceuticals shares declined after beating earnings expectations but cutting its Cortrophin outlook. Cortrophin outlook cut directly pressures future revenue forecasts and triggers share price drop.

4 , 6:50 AM
ANI Pharmaceuticals reported record second quarter 2026 financial results. Record quarterly earnings signal strong operational performance and will likely drive positive stock movement.

3 transcript app.moby.co, 5:22 PM
ANI Pharmaceuticals, Inc. released Q2 2026 earnings call details covering financial results, operational updates and forward guidance. Quarterly earnings updates deliver financial metrics that moderately shift near-term investor sentiment and valuation.

3 www.marketbeat.com, 10:04 AM
ANI Pharmaceuticals Q2 earnings call highlighted financial performance, revenue figures, product updates, and management outlook on operations and growth. Q2 earnings details can influence short-term stock movements and provide operational insights.

3 , 9:30 AM
ANI Pharmaceuticals (ANIP) Q2 earnings results featured key metrics versus Wall Street estimates. Q2 earnings metrics versus estimates can shift near-term investor sentiment and trading activity for ANIP.

3 , 8:05 AM
ANI Pharmaceuticals beat Q2 earnings and revenue estimates. Q2 earnings and revenue beat supports positive near-term stock movement for ANI Pharmaceuticals.

3 , 7:12 AM
ANI Pharmaceuticals reported Q2 CY2026 sales above estimates, yet stock declined on weak guidance. Sales beat offset by weak guidance drove stock drop and near-term investor sentiment shift.

31 Jul

3 , 10:00 AM
ANI Pharmaceuticals (ANIP) is scheduled to report earnings next week with Wall Street expecting earnings growth. Earnings growth expectations may produce moderate short-term effects on ANIP stock performance and sentiment.

25 Jul

4 , 1:09 PM
Positive ILUVIEN Phase 4 NIU-PS data emerges for ANI Pharmaceuticals, potentially altering the bull case for the company. Positive Phase 4 ILUVIEN NIU-PS data strengthens ANI Pharmaceuticals product prospects and growth outlook.

4 , 12:19 AM
ANI Pharmaceuticals reported positive SYNCHRONICITY trial results, leading to questions on whether ANIP stock now represents a bargain. Positive SYNCHRONICITY trial results strengthen ANI Pharmaceuticals' product pipeline and growth prospects.

24 Jul

3 , 4:01 PM
ANI Pharmaceuticals shows two favorable factors for potential growth and one risk that could affect investor decisions. Discussed factors point to moderate effects on ANIP operations and market position without major trajectory shifts.

13 Jul

4 , 6:50 AM
ANI Pharmaceuticals announced positive six-month topline data from the Phase 4 SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis patients. Positive Phase 4 data supports expanded use and revenue growth for the implant product.

10 Jun

3 Zacks, 1:24 PM
ANI Pharmaceuticals is pushing Cortrophin for acute gout treatment. Cortrophin push into acute gout opens a new market opportunity for ANI Pharmaceuticals.

5 Jun

3 Simply Wall St., 5:08 AM
ANI Pharmaceuticals recalled its Estradiol Gel, shifting investor views on the strength of its quality-control investments and raising doubts over product reliability. Estradiol Gel recall questions ANIP quality control strength and may dampen future performance outlook.

1 Jun

4 transcript www.fool.com, 1:25 PM
ANI Pharmaceuticals (ANIP) released its Q1 2026 earnings call transcript covering financial results, operations and outlook. Earnings call transcript discloses quarterly results and guidance that directly affect investor views and share performance.

19 May

3 Simply Wall St., 2:50 PM
ANI Pharmaceuticals reported earnings that mask underlying weaknesses, pointing to softer profitability and operational results than headline numbers indicate. Negative reinterpretation of ANI earnings can pressure near-term stock valuation and investor sentiment without altering long-term fundamentals.

17 May

4 Simply Wall St., 11:12 AM
ANI Pharmaceuticals raised its 2026 guidance and announced a new share buyback program, improving its investment outlook and signaling stronger future performance. Raised 2026 guidance combined with a new buyback directly supports higher earnings expectations and share price support.

16 May

3 Simply Wall St., 10:06 PM
ANI Pharmaceuticals shifts focus to rare diseases while increasing share buybacks as insiders sell stock. Rare-disease refocus and buybacks can lift long-term prospects while insider sales add near-term pressure.

15 May

4 Zacks, 11:46 AM
ANI Pharmaceuticals shifts focus to rare diseases, unveiling a strategic playbook targeting 2026 growth amid pipeline advancements and market positioning. Rare disease pivot and 2026 playbook represent major strategic moves poised to alter competitive trajectory and boost long-term prospects.

11 May

4 , 11:27 AM
ANI Pharmaceuticals (ANIP) Q1 earnings and sales beat estimates, prompting a raised 2026 outlook. Beating Q1 estimates and raising 2026 outlook indicates strong financial momentum likely to enhance investor sentiment and stock trajectory.

9 May

4 Simply Wall St., 2:12 PM
Recent pipeline developments at ANI Pharmaceuticals (ANIP) raise questions about whether the stock remains attractively priced. Pipeline developments signal major strategic progress that could significantly boost ANIP's competitive position and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us